<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ceftobiprole (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ceftobiprole (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ceftobiprole (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="12126" href="/d/html/12126.html" rel="external">see "Ceftobiprole (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52868969"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Zevtera</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F50931645"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Cephalosporin (Fifth Generation)</li></ul></div>
<div class="block doa drugH1Div" id="F6698412"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>No dosage adjustment necessary based on body weight (manufacturer’s labeling).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8f9ec9fd-fc1b-4a1f-868a-eeb97c396e6e">Bloodstream infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bloodstream infection (alternative agent) (off-label use):</b>
<i>Pathogen-directed therapy for S. aureus, including methicillin-resistant S. aureus:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: </b>500 mg every 6 hours for 8 days, followed by 500 mg every 8 hours thereafter (Holland 2023); treat uncomplicated <i>S. aureus</i> bacteremia for ≥14 days starting from day of first negative blood culture, with longer courses warranted for endocarditis or metastatic sites of infection (IDSA [Mermel 2009]).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7792e77c-7758-4230-a81e-dc7dd3a6acb9">Pneumonia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Community-acquired pneumonia:</i> IV:</b> 500 mg every 8 hours (manufacturer's labeling). Total duration (including oral step-down therapy) is a minimum of 5 days (or 7 days if methicillin-resistant <i>S. aureus</i> [MRSA] is isolated); patients should be clinically stable with normal vital signs prior to discontinuation (IDSA/ATS [Metlay 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Hospital-</i>
<i>acquired pneumonia (alternative agent):</i></b>
<i>As pathogen-directed therapy for MRSA: </i>
<b>Note:</b> Not recommended for patients with ventilator-associated pneumonia based on lower cure rate (Awad 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> 500 mg every 8 hours (Awad 2014). Duration of therapy varies based on disease severity and response to therapy; treatment is typically given for 7 days (IDSA/ATS [Kalil 2016]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990051"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function: IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> CrCl should be based on the Cockcroft-Gault formula using actual body weight (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>If recommended dose is 500 mg every 6 hours:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 50 to 150 mL/minute: No dosage adjustment necessary (Hamed 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to &lt;50 mL/minute: 500 mg every 8 hours (Hamed 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: 250 mg every 8 hours (Hamed 2020).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>If recommended dose is 500 mg every 8 hours:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 50 to 150 mL/minute: No dosage adjustment necessary (Hamed 2020; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 to &lt;50 mL/minute: 500 mg every 12 hours (Hamed 2020; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: 250 mg every 12 hours (Hamed 2020; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:6em;">End-stage kidney disease without dialysis: 250 mg every 24 hours (manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Augmented renal clearance (CrCl &gt;150 mL/minute): IV: </b>No dosage adjustment necessary; however, duration of infusion should be extended to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Dialyzable (~70% [Torres 2016]): <b>IV: </b>250 mg every 24 hours (Hamed 2020; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b>
<b>IV:</b> 250 mg every 24 hours (Hamed 2020).</p></div>
<div class="block doha drugH1Div" id="F50987256"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F6698427"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F6696015"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Endocrine &amp; metabolic: Hyponatremia (≤11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Phlebitis (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (≤3%), dizziness (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (2% to 7%), diarrhea (3% to 6%), vomiting (2% to 6%), dysgeusia (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (≤5%), increased serum aspartate aminotransferase (≤5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion site reaction (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (1% to 8%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abdominal pain, agitation, agranulocytosis, anaphylaxis, anemia, anxiety, asthma, <i>Clostridioides difficile</i> colitis, drowsiness, dyspepsia, dyspnea, eosinophilia, fever, hypokalemia, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum glucose, increased serum triglycerides, insomnia, leukopenia, muscle spasm, nightmares, panic attack, peripheral edema, pharyngolaryngeal pain, pruritus, renal failure syndrome, seizure, thrombocythemia, thrombocytopenia</p></div>
<div class="block coi drugH1Div" id="F6696011"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ceftobiprole, other cephalosporins, or any component of the formulation; immediate and severe hypersensitivity (eg, anaphylaxis) to any other type of beta-lactams (eg, penicillins or carbapenems)</p></div>
<div class="block war drugH1Div" id="F6696012"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte abnormalities: Sodium content should be considered in patients requiring sodium restriction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hemolytic anemia: Seroconversion from a negative to a positive direct Coombs test has been reported. Hemolytic anemia was not reported in clinical studies; however, if anemia develops during or after treatment, consider drug-induced hemolytic anemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: <b>[Canadian Boxed Warning]: Anaphylaxis, occasionally fatal, has been reported with use of beta-lactam antibiotics, including ceftobiprole</b>; <b>individuals with prior hypersensitivity reactions to multiple allergens may be at increased risk. Prior to initiating therapy with ceftobiprole, carefully assess patient for prior history of hypersensitivity to cephalosporins, penicillins, or other allergens</b>. Discontinue use immediately with onset of signs/symptoms of allergic reaction and institute supportive emergency measures. Use is contraindicated in patients with a prior anaphylactic reaction to beta-lactam antibiotics. Use caution if initiating therapy in patients with a history of nonsevere hypersensitivity to other beta-lactam drugs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal toxicity: Reversible renal toxicity was observed in animals receiving high doses and was associated with precipitation of drug-like material in the distal tubules. Clinical significance is unknown; correct hypovolemia to maintain normal urinary output in patients receiving ceftobiprole.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Use may result in fungal or bacterial superinfection. <i>Clostridioides</i>
<i>difficile</i>–associated diarrhea (CDAD) and pseudomembranous colitis have been reported with use; consider this diagnosis in patients who develop diarrhea during or after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment. Dosage adjustment is required with CrCl &lt;50 mL/minute and prolongation of infusion is recommended in patients with CrCl &gt;150 mL/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a history of seizure or CNS disorder; seizure activity associated with use has most commonly been observed in these patient populations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Ceftobiprole is not effective in treatment of ventilator-associated pneumonia (VAP). Clinical efficacy data are limited in multidrug resistant <i>Streptococcus</i>
<i> pneumoniae</i>-infected pneumonia patients; not recommended in treatment of hospital-acquired pneumonia (HAP) caused by this pathogen. Ceftobiprole is susceptible to hydrolysis that may be produced by <i>Enterobacteriaceae</i> (eg, extended-spectrum beta-lactamases [ESBLs], serine carbapenemases, class B metallo-beta-lactamases); consider prevalence of <i>Enterobacteriaceae</i>-producing ESBLs when prescribing ceftobiprole.</p>
<p style="text-indent:-2em;margin-left:4em;">• Precipitation: May occur when mixed with calcium-containing solutions in the same IV administration line. Do not mix or simultaneously administer ceftobiprole and calcium-containing solutions (except Lactated Ringer's) in the same IV line.</p></div>
<div class="block prod-avail drugH1Div" id="F50931709"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the United States.</p></div>
<div class="block geq drugH1Div" id="F53040750"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F52868970"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zevtera: 500 mg (1 ea)</p></div>
<div class="block adm drugH1Div" id="F6698417"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Administer by IV infusion over 2 hours. Administer over 4 hours in patients with a CrCl &gt;150 mL/minute. Refrigerated infusions should be brought to room temperature prior to administration.</p></div>
<div class="block use drugH1Div" id="F6696007"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired (CAP) and hospital-acquired (HAP): </b>Treatment of CAP caused by <i>Staphylococcus aureus</i> (including methicillin-resistant <i>S. aureus</i> [MRSA]), <i>Streptococcus pneumoniae</i>, <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, and <i>Haemophilus influenzae</i>; treatment of HAP, excluding ventilator-associated pneumonia (VAP), caused by <i>S. aureus</i> (including MRSA), <i>S. pneumoniae</i>, <i>E. coli</i>, and <i>K. pneumoniae</i>.</p></div>
<div class="block off-label drugH1Div" id="F58862081"><span class="drugH1">Use: Off-Label: Adult</span><p>Bloodstream infection</p></div>
<div class="block mst drugH1Div" id="F50931642"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ceftobiprole may be confused with ceftaroline or ceftibuten.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b>ALERT: Canadian Boxed Warning</b>: Health Canada-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F51115015"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of OAT1/3</p></div>
<div class="block dri drugH1Div" id="F6754086"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Furosemide: May enhance the nephrotoxic effect of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F6696008"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F50931670"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ceftobiprole is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F6698420"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Renal function; signs/symptoms of hypersensitivity</p></div>
<div class="block pha drugH1Div" id="F6698415"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Prodrug converted in vivo to active drug with bactericidal activity by binding to one or more of the penicillin-binding proteins (PBPs), including PBP2a in methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), PBP2b in <i>Streptococcus pneumoniae</i> (penicillin-intermediate), PBP2x in <i>S. pneumoniae </i>(penicillin resistant), and PBP5 in <i>Enterococcus faecalis.</i></p></div>
<div class="block phk drugH1Div" id="F6698404"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Ceftobiprole systemic clearance is 40% greater in patients with CrCl &gt;150 mL/minute and V<sub>d</sub> is 30% larger.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 18 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 16% (concentration independent)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Ceftobiprole medocaril sodium (prodrug) rapidly metabolized by plasma esterases to ceftobiprole (active drug), which undergoes minimal metabolism to an inactive metabolite</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: 89% (83% as active drug, 5% as inactive metabolite, &lt;1% as unchanged prodrug)</p></div>
<div class="block phksp drugH1Div" id="F51192042"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Ceftobiprole AUC is 2.5- and 3.3-fold higher in patients with CrCl 30 to &lt;50 mL/minute and CrCl &lt;30 mL/minute, respectively.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961939"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Mabelio</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Mabelio</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Zeftera</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Zevtera</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24723282">
<a name="24723282"></a>Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia.<i> Clin Infect Dis</i>. 2014;59(1):51-61. doi:10.1093/cid/ciu219<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftobiprole-united-states-not-available-drug-information/abstract-text/24723282/pubmed" id="24723282" target="_blank">24723282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31918579">
<a name="31918579"></a>Hamed K, Engelhardt M, Jones ME, et al. Ceftobiprole versus daptomycin in <i>Staphylococcus aureus</i> bacteremia: a novel protocol for a double-blind, phase III trial. <i>Future Microbiol</i>. 2020;15(1):35-48. doi:10.2217/fmb-2019-0332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftobiprole-united-states-not-available-drug-information/abstract-text/31918579/pubmed" id="31918579" target="_blank">31918579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37754204">
<a name="37754204"></a>Holland TL, Cosgrove SE, Doernberg SB, et al; ERADICATE Study Group. Ceftobiprole for treatment of complicated <i>Staphylococcus aureus</i> bacteremia. <i>N Engl J Med</i>. 2023;389(15):1390-1401. doi:10.1056/NEJMoa2300220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftobiprole-united-states-not-available-drug-information/abstract-text/37754204/pubmed" id="37754204" target="_blank">37754204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27418577">
<a name="27418577"></a>Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. <i>Clin Infect Dis</i>. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftobiprole-united-states-not-available-drug-information/abstract-text/27418577/pubmed" id="27418577" target="_blank">27418577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2009;49(1):1-45. doi:10.1086/599376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftobiprole-united-states-not-available-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19489710">
<a name="19489710"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Respir Crit Care Med</i>. 2019;200(7):e45-367. doi:10.1164/rccm.201908-1581ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftobiprole-united-states-not-available-drug-information/abstract-text/19489710/pubmed" id="19489710" target="_blank">19489710</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27272266">
<a name="27272266"></a>Torres A, Mouton JW, Pea F. Pharmacokinetics and dosing of ceftobiprole medocaril for the treatment of hospital- and community-acquired pneumonia in different patient populations. <i>Clin Pharmacokinet</i>. 2016;55(12):1507-1520. doi:10.1007/s40262-016-0418-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ceftobiprole-united-states-not-available-drug-information/abstract-text/27272266/pubmed" id="27272266" target="_blank">27272266</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Zevtera (ceftobiprole) [product monograph]. Blainville, Québec, Canada: AVIR Pharma Inc; April 2021.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9001 Version 57.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
